# An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours

> **NCT06695689** · EARLY_PHASE1 · RECRUITING · sponsor: **Suzhou BlueHorse Therapeutics Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** LM303

## Key facts

- **NCT ID:** NCT06695689
- **Lead sponsor:** Suzhou BlueHorse Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-17
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06695689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06695689, "An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06695689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*